AstraZeneca’s new weight-loss pill, AZD5004, shows promise in early trials with tolerable side effects, advancing to Phase II studies focused on reducing obesity.
AstraZeneca reported on Monday that its experimental weight-loss pill, AZD5004, licensed from China's Eccogene for up to $2 billion, was found safe and tolerable in an early-stage trial.
The study, which included 72 participants who were either healthy or had type 2 diabetes, showed side effects consistent with other GLP-1 drugs, such as nausea and vomiting. Based on these findings, AstraZeneca has advanced AZD5004 to Phase II trials focused on weight reduction in overweight and obese individuals, with completion expected by late 2025.
Unlike injectable treatments from competitors Eli Lilly and Novo Nordisk, AZD5004 is a small molecule pill that can be combined with other medications and taken with or without food, offering potential advantages for patients with additional health conditions.
AstraZeneca also shared early-stage data on other obesity drugs, AZD6234 and AZD9550, which target different hunger-related hormones and will undergo further Phase II testing through 2026.
Meanwhile, Viking Therapeutics released early trial results for its own oral obesity drug, which briefly boosted its stock before a decline.
A CIA review has identified procedural flaws in a 2016 assessment that Russia sought to help Donald Trump win the U.S. presidency, but it did not chal...
A bus operated by Kern Transit overturned on Monday morning after hitting railway tracks alongside Sierra Highway in Lancaster, California. Approximat...
Scientists have sequenced the full genome of a man buried in pharaonic Egypt over 4,500 years ago, revealing that about 20% of his ancestry came from ...
A federal judge has halted President Donald Trump’s controversial asylum ban at the US-Mexico border, ruling that the move oversteps his executive p...
Vietnam is set to confirm the purchase of 50 Boeing planes worth $8 billion, alongside agreements to import $2.9 billion in U.S. agricultural products...
A groundbreaking study presented at ASCO reveals that AstraZeneca’s experimental pill camizestrant, when used based on blood test results, can halve the risk of breast cancer progression or death—potentially reshaping treatment for patients with hormone receptor-positive, HER2-negative breast cancer
AstraZeneca, opens new tab said it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.
The U.S. economy faces a 40% risk of recession in the second half of 2025, JP Morgan analysts said on Wednesday, citing rising tariffs and stagflation concerns.
A magnitude 5.5 earthquake struck off Japan’s Tokara Islands on Wednesday, with no tsunami warning issued but residents advised to remain vigilant.
China has ramped up efforts to protect communities impacted by flood control measures, introducing stronger compensation policies and direct aid from the central government.
The European Commission is set to propose allowing carbon credits from other countries to count towards the EU’s 2040 climate target, according to a leaked internal document.
Severe rain in Venezuela has caused rivers to overflow and triggered landslides, sweeping away homes and collapsing a highway bridge, with five states affected and no casualties reported so far.
France will impose its toughest outdoor smoking restrictions starting Monday, banning smoking at beaches, parks, playgrounds, and bus stops.
Scientists in Australia and the U.S. have developed an AI tool that could transform cancer care by revealing the hidden diversity of tumour cells and guiding more targeted therapies.
Singapore has launched its largest-ever study on paediatric food allergies, aiming to better understand and address the growing burden of allergic reactions among children.
Bill Gates says his foundation will not compensate for funding shortfalls caused by U.S. and UK aid cuts to global vaccination efforts, warning of rising child mortality as a result.
The world is facing a health financing emergency as global health investment risks falling to its lowest level in a decade, the World Health Organization (WHO) warned.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment